NICE
NICE recommends PTC Therapeutics’ Translarna to treat Duchenne muscular dystrophy
April 18, 2016Sales and Marketing DMD, Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, regulation
Shares in drug maker PTC Therapeutics (Nasdaq: PTCT) jumped after the National Institute for Health and Care Excellence (NICE) backed …
NICE issues new guidance on the safer use of controlled drugs
April 13, 2016Medical Communications NICE, controlled drugs, guidance
The National Institute for Health and Care Excellence (NICE) has issued guidance bringing together legislation and existing advice on the …
Bristol-Myers Squibb cancer immunotherapy Opdivo approved in EU
April 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, EU, NICE, approval, immunotherapy, opdivo
Bristol-Myers Squibb has announced that its potentially life-extending cancer immunotherapy, Opdivo (nivolumab), has been approved by the European Commission to …
NICE draft guidance says ‘no’ to cystic fibrosis drug Orkambi
March 23, 2016Research and Development, Sales and Marketing NICE, Orkambi, Vertex, cystic fibrosis
NICE has issued draft guidance not recommending Vertex’s Orkambi (lumacaftor/ivacaftor) for use on the National Health Service (NHS) in England …
Novartis’s heart failure drug given final recommendation by NICE
March 21, 2016Manufacturing and Production, Research and Development Entresto, NICE, Novartis, approval, draft, guidance, heart failure, heart failure drug
The National Institute for Health and Care Excellence (NICE) has issued its final guidance on Entresto (sacubritil/valsartan), a heart failure …
NICE approves Janssen’s Zytiga for prostate cancer before chemo
March 21, 2016Sales and Marketing Janssen, NICE, Zytiga, prostate cancer
The National Institute for Health and Care Excellence (NICE) has recommended the use of Janssen’s Zytiga (abiraterone acetate) to treat …
Wales approve pancreatic cancer drug for use despite NICE rejection in England
March 18, 2016Medical Communications, Research and Development Abraxane, Celgene, England, NHS, NICE, Wales, approval
Celgene (Nasdaq: CELG) has announced that Abraxane, in combination with gemcitabine, will continue to be an available treatment option for …
Amgen skin cancer drug Imlygic rejected by NICE
March 16, 2016Research and Development Amgen, Imlygic, NICE, melanoma, skin cancer
NICE has rejected Amgen’s drug Imlygic (talimogene laherparepvec) in draft as a treatment for advanced melanoma that has spread and …
BMS criticises Scottish regulator over Opdivo skin cancer ‘no’
March 7, 2016Medical Communications, Research and Development Bristol-Myers Sqibb, NICE, SMC, melanoma, opdivo
Bristol-Myers Squibb says the Scottish Medicines Consortium’s (SMC) decision not to recommend its immunotherapy Opdivo (nivolumab) as a monotherapy for …
Janssen slams NICE decision on Imbruvica
March 2, 2016Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica
Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …
MHRA approves new indication for MSD’s Ezetrol
February 26, 2016Medical Communications, Research and Development, Sales and Marketing MHRA, MSD, NICE, ezetrol
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for MSD’s Ezetrol (ezetimibe), making it …
Novartis says CDF proposals place “unreasonable” risk on pharma
February 10, 2016Medical Communications, Research and Development, Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Novartis
Novartis has criticised some of the proposed changes to the way in which the UK Cancer Drugs Fund (CDF) is …
NICE changes mind on Amgen’s cholesterol drug
February 8, 2016Manufacturing and Production, Sales and Marketing Amgen, NICE, Repatha
NICE has changed its mind on Amgen’s cholesterol-busting drug Repatha (evolocumab), and decided to recommend approval of the treatment in …
NICE rejects cholesterol drug Praluent in draft guidance
February 8, 2016Research and Development, Sales and Marketing NICE, Regeneron, Sanofi, cholesterol
NICE has published draft guidance not recommending Sanofi/Regeneron’s Praluent (alirocumab) as an option for people with high cholesterol (primary hypercholesterolaemia …
UK lung cancer patients get early access to breakthrough BMS drug
February 5, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, MHRA, NICE, eams, opdivo
UK lung cancer patients are to get access to Bristol Myers-Squibb’s Opdivo (nivolumab) through the Early Access to Medicines Scheme …
Latest content
FibroFind appoints Lee Borthwick as CEO
